Clinical trial
An Open-Label, Phase 2b, Global Multicenter Cohort Trial to Assess the Safety and Efficacy of Zipalertinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Exon 20 Insertion and Uncommon/Single or Compound Epidermal Growth Factor Receptor Mutations.
NCT05967689 is registered in ClinicalTrials.gov with Taiho Oncology, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label, Phase 2b, Global Multicenter Cohort Trial to Assess the Safety and Efficacy of Zipalertinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Exon 20 Insertion and Uncommon/Single or Compound Epidermal Growth Factor Receptor Mutations.
- Lead sponsor
- Taiho Oncology, Inc.
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- July 31, 2023
- Completion date
- December 31, 2028
- Enrollment
- 220 (estimated)
- Sites
- 80
Conditions
As the registry lists them; a condition with its own page is linked.
advanced or metastatic nsclc harboring epidermal growth factor receptor (egfr) exon 20 insertion (ex20ins) mutations